Organization (Industry)
Rose Research Center (United States)
ClinicalTrials.gov lists Rose Research Center (United States) as lead sponsor of 13 trials. It has 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Rose Research Center (United States): 13 lead-sponsored trials and 1 legal-entity registration.
Disease areas (4)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Substance-Related Disorders | 7 |
| Tobacco Use Disorder | 6 |
| Nausea | 1 |
| Parasomnias | 1 |
Trials by start year as sponsor or collaborator (7)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 4 |
| 2021 | 4 |
| 2020 | 2 |
| 2019 | 4 |
| 2018 | 1 |
| 2017 | 1 |
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Hydroxyzine Pill | 1 |
| Varenicline Pill | 1 |
| Bupropion | 2 |
| Zonisamide | 2 |
| Varenicline | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 56% hit target (n=9) | 40% on time (n=10) |
Journals published in (13)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Cochrane database of systematic reviews | 4 |
| Annals of epidemiology | 1 |
| Annals of internal medicine | 1 |
| Annual review of public health | 1 |
| BMC public health | 1 |
Showing 5 of 13 journals.
Financing and grant events (1)
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2023-07-05 | NIH grant | 579,371 | Reporter |
Latest dated events (18)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2024-08-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-12-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-10-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-09-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-07-05 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 18 events.
CLIA clinical laboratory certificates (2)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| ROSE RESEARCH CENTER, LLC | Certificate of waiver | Active |
| ROSE RESEARCH CENTER, LLC | Certificate of waiver | Active |
Biomarker capability evidence (8)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CREBBP | Trial collaborator | Named in trial exclusion criteria |
| EMB | Trial sponsor | Named in trial exclusion criteria |
| EMB | Trial collaborator | Named in trial exclusion criteria |
| PAG1 | Trial collaborator | Named in trial exclusion criteria |
| CREBBP | Trial collaborator | Mentioned in trial text |
Showing 5 of 8 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, and biomarkers this organization publishes on.